Patients, Public and Policy. On these pages you can find general information on genetic testing and genetic services for patients, their family and for the general public. Because it is important that new guidelines and recommendations find their way into European standards and regulations, EuroGentest is also actively involved in policy work.

Manifold plays with all. Keep up with the fastest Enterprise DBMS and run ahead of all others. Enjoy huge capacity and speed - hundreds of GB on your desktop. Manifold system 8010 ultimate edition.

Patient leaflets EuroGentest has developed a series of 15 leaflets to provide general information for patients and families about genetics and genetic testing. Can either be downloaded and printed out, or you can look at the information online by choosing the HTML version.

Select your language (more than 30 languages are available!): • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • NEWThe Council of Europe has developed a general leaflet on Genetic Tests for Health Purposes with the support of Eurogentest and the European Society of Human Genetics (click ). Two new leaflets have been created on non-invasive prenatal testing (NIPT): One generic leaflet () and one more specific (). Direct-to-consumer genetic testing When a test is offered to patients through a private company instead of health care providers, this test is called a direct-to-consumer test (DTC). Although this makes genetic testing available for a broad audience, one must be aware of the risks and limitations of these tests when offered outside of health care.

Click for more information on DTC. NEWEuroGentest developed a simple tool for clinicians that will help them to understand and advise patients about the many issues inherent in the use of such services (click. Individuals considering using a DTC test may also find this tool useful.

Mission and Vision There is an impelling need to speed up the transfer of scientific results from the laboratory to the clinic: clinicians require it, society demands it, and scientists must respond. Each interest group depends on the other two to achieve this aim. This is why we established the Molecular Medicine for Care (MMC) program at IEO.

Through the mutual collaboration of scientists, clinicians and patients, we are driving discoveries from the basic research programs conducted in the laboratory of Pier Paolo Di Fiore [1-11] into the clinical domain, through four scientific programs that focus on breast, lung and ovarian cancers. While these are being carried forward, we have brewing in the pipeline a number of other new discovery projects that will ultimately translate into the improved clinical management of breast, lung, ovarian and prostate cancer. Our current scientific programs aim to: 1) Identify stem cell markers for the diagnosis, prognosis and therapeutic stratification of breast, lung and ovarian cancers. 2) Develop a blood test for the early diagnosis of lung cancer. 3) Understand breast and ovarian cancer for early diagnosis. 4) Make new discoveries to increase our molecular understanding of cancer and feed new translational research projects. MMC Scientific Programs Stem cell markers for the diagnosis, prognosis and therapeutic stratification of breast, lung and ovarian cancer Lead scientific contacts Breast cancer: Salvatore Pece, Fabrizio Bianchi, Stefano Confalonieri, Manuela Vecchi Lung cancer: Elena Belloni Ovarian Cancer: Ugo Cavallaro Stem cells are a rare population of cells necessary for tissue integrity and regeneration in case of injury.